PHARMACOKINETICS OF DILEVALOL AND ITS CONJUGATES IN MAN - ASSAY-METHOD FOR PLASMA, BLOOD, URINE AND BILE SAMPLES AND PRELIMINARY PHARMACOKINETIC STUDIES
M. Neubeck et al., PHARMACOKINETICS OF DILEVALOL AND ITS CONJUGATES IN MAN - ASSAY-METHOD FOR PLASMA, BLOOD, URINE AND BILE SAMPLES AND PRELIMINARY PHARMACOKINETIC STUDIES, Arzneimittel-Forschung, 43-2(9), 1993, pp. 953-957
The renal and biliary excretion of the beta-adrenoceptor blocking agen
t dilevalol (CAS 75659-07-3) and its conjugates was examined in a prel
iminary pharmacokinetic study. Plasma, urine and bile dilevalol concen
trations were determined with a simplified procedure that is based on
alkaline liquid-liquid extraction using diethyl ether and subsequent r
eversed-phase HPLC separation of the reconstituted samples (on a PRP-1
stationary phase using a mixture of methanol and pH 9.8 carbonate buf
fer as mobile phase). Triamterene was used as internal standard. The q
uantification of the conjugates was accomplished indirectly via enzyma
tic hydrolysis (glusulase) with and without addition of the beta-glucu
ronidase inhibitor 1,4-saccharolactone (at a final concentration of 5.
5 mmol/l). In the pharmacokinetic study healthy volunteers and cholect
ystectomised patients with a T-drain received a single oral dose of 20
0 mg dilevalol. Furthermore, to healthy volunteers an i.v. dose of 60
mg dilevalol was given in order to estimate the absolute bioavailabili
ty. From the obtained data the systemic plasma clearance was calculate
d to be 1708 ml/min. The oral bioavailability was calculated to be 16%
. The log concentration-time curves of the metabolites paralleled thos
e of dilevalol in the terminal section with average terminal half-live
s of approx. 5h. In volunteers the fractions of the dose excreted rena
lly were 0.5% for parent drug, 23% for the glucuronide(s) and 8% for t
he sulfate. The corresponding values found for the patients were not s
ignificantly different. In the patients' bile only 1.2% of the total d
ose were found (0.03% dilevalol, 1.1% dilevalol glucuronide(s), 0.1% d
ilevalol sulfate). The total fraction of the p.o. dose excreted in uri
ne and bile - either as dilevalol or as conjugate - amounted to 30. It
was hence concluded that formation of phase-I-metabolites must be an
important clearance pathway.